InvestorsHub Logo
Followers 45
Posts 5119
Boards Moderated 0
Alias Born 01/27/2012

Re: McMagyar post# 109556

Saturday, 06/24/2017 2:40:46 PM

Saturday, June 24, 2017 2:40:46 PM

Post# of 458561
Mc I completely agree. As we await these trials to start up I keep trying to piece the Dr.'s roadmap together. I agree and believe much of your theory about adjunct therapy. The Dr, SAB, and BOD are not trying to come up with a treatment for any one of these upcoming trial diseases but rather are showing or teasing out the everyday life benefits for all of them and SO MANY MORE TO COME, IMO. This wont ALWAYS show up on a test with numbers associated with it (like Dr. Mcfarlan commented), quality of life is what should be the end goal and that is what we are shooting for IMO. I believe Anavex will continue to show, aside from anti convulsive properties, improvements in daily life like gait, cognition, mood, better interaction with people, motor skills.......all the other "unexpected therapeutic effects" documented in the phase 2a ALZ trial and soon possibly more in the Rett and Parkinson trial too.
So those here that want to dissect word for word what the GOOD Dr. has said or hasn't said in the data that is incomplete or insignificant,....go right on ahead! We haven't seen anything yet but "will soon see" more than the "tip of the ICEBERG"!

Also who knows, we may have 2,5,10 ODD applications just waing in the wings of the FDA "backlog".

Tred
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AVXL News